We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
Read MoreHide Full Article
Key Takeaways
Veracyte shares fell 25.3% in a month despite 15.4% revenue growth and 22.7% higher adjusted earnings.
VCYT's Decipher and Afirma posted double-digit sales growth, while newer oncology launches expand its runway.
VCYT's premium valuation and reimbursement risks are tempered by $485.2M in cash and no current debt.
Veracyte, Inc. (VCYT - Free Report) shares have fallen 25.3% in the past month even as the diagnostics company continues to post double-digit testing growth and stronger earnings. Second-quarter 2026 revenues rose 15.4% year over year, while adjusted earnings increased 22.7%.
The sell-off has improved the entry price, but valuation and commercialization risks still matter. Investors must weigh durable demand for Decipher and Afirma, newer oncology launches and positive estimate revisions against reimbursement uncertainty and execution demands.
VCYT’s Core Tests Still Show Strong Demand
Decipher Prostate remains the largest growth engine. Second-quarter revenues increased 20% year over year to $91.9 million as test volume rose 17% to about 29,700. Orders per physician reached a record high, while new ordering physicians also increased.
Afirma added another layer of growth. Second-quarter revenues climbed 18% as volume rose 10% to about 18,600 tests, supported by higher utilization, share gains and better reimbursement. Veracyte expects Afirma revenues to increase about 12% to 14% in 2026.
Veracyte’s New Launches Expand the Growth Runway
Veracyte launched Prosigna LDT in the United States in the second quarter after presenting results from the OPTIMA Phase III trial. The company is engaging with more than 100 institutions and is expanding its sales force ahead of plan.
Based on short-term price targets offered by 11 analysts, the average price target for Veracyte comes to $57.82. The average price target represents an increase of 36.66% from the last closing price of $42.31.
Image Source: Zacks Investment Research
TrueMRD, launched in June for muscle-invasive bladder cancer, already has Medicare coverage for recurrence monitoring after radical cystectomy. The competitive field is active. Natera, Inc. (NTRA - Free Report) has an FDA-approved Signatera companion diagnostic for molecular residual disease in muscle-invasive bladder cancer, while Guardant Health, Inc. (GH - Free Report) is expanding liquid-biopsy and recurrence-monitoring capabilities across oncology.
VCYT Faces Reimbursement and Execution Risks
Prosigna has not yet secured Medicare reimbursement, and Veracyte excluded both Prosigna LDT and TrueMRD revenues from 2026 guidance because commercialization remains early. Decipher also faces softer demand in low-risk prostate cancer following guideline changes.
The Veracyte SAS exit adds another reset. Biopharmaceutical and other revenues fell to $0.8 million in the second quarter from $4.3 million a year earlier, increasing dependence on testing revenues. Higher investment adds execution pressure, with non-GAAP research and development expense rising to $26.3 million from $14.3 million.
Veracyte’s Valuation Leaves Less Room for Error
The recent decline has not made VCYT inexpensive relative to its group. The stock trades at 5.3X forward 12-month sales, above the Zacks sub-industry’s 4.2X multiple and slightly above its five-year median of 5.2X.
Image Source: Zacks Investment Research
That premium leaves less room for setbacks in reimbursement or launch execution. Still, the balance sheet provides flexibility. Veracyte ended the second quarter with $485.2 million in cash, cash equivalents and short-term investments and no current debt.
VCYT’s Signals Mix Strength With Caution
The sell-off has created a better price than a month ago, but the case is not purely valuation driven. Core test demand, raised 2026 revenue guidance and a debt-free balance sheet support the operating outlook, while reimbursement and commercialization risks argue for selectivity.
VCYT currently carries a Zacks Rank #1 (Strong Buy), reflecting favorable near-term earnings-estimate revisions. The Zacks Consensus Estimate for 2026 earnings has risen 3.9% in the past four weeks. Its Momentum Score of B is supportive, but the Growth Score of C, Value Score of D and VGM Score of D show that the stock does not score favorably across all investing styles. The combination points to stronger near-term estimate momentum, tempered by valuation and broader style considerations.
View the Zacks #1 Rank List
Image: Bigstock
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
Key Takeaways
Veracyte, Inc. (VCYT - Free Report) shares have fallen 25.3% in the past month even as the diagnostics company continues to post double-digit testing growth and stronger earnings. Second-quarter 2026 revenues rose 15.4% year over year, while adjusted earnings increased 22.7%.
The sell-off has improved the entry price, but valuation and commercialization risks still matter. Investors must weigh durable demand for Decipher and Afirma, newer oncology launches and positive estimate revisions against reimbursement uncertainty and execution demands.
VCYT’s Core Tests Still Show Strong Demand
Decipher Prostate remains the largest growth engine. Second-quarter revenues increased 20% year over year to $91.9 million as test volume rose 17% to about 29,700. Orders per physician reached a record high, while new ordering physicians also increased.
Afirma added another layer of growth. Second-quarter revenues climbed 18% as volume rose 10% to about 18,600 tests, supported by higher utilization, share gains and better reimbursement. Veracyte expects Afirma revenues to increase about 12% to 14% in 2026.
Veracyte’s New Launches Expand the Growth Runway
Veracyte launched Prosigna LDT in the United States in the second quarter after presenting results from the OPTIMA Phase III trial. The company is engaging with more than 100 institutions and is expanding its sales force ahead of plan.
Based on short-term price targets offered by 11 analysts, the average price target for Veracyte comes to $57.82. The average price target represents an increase of 36.66% from the last closing price of $42.31.
Image Source: Zacks Investment Research
TrueMRD, launched in June for muscle-invasive bladder cancer, already has Medicare coverage for recurrence monitoring after radical cystectomy. The competitive field is active. Natera, Inc. (NTRA - Free Report) has an FDA-approved Signatera companion diagnostic for molecular residual disease in muscle-invasive bladder cancer, while Guardant Health, Inc. (GH - Free Report) is expanding liquid-biopsy and recurrence-monitoring capabilities across oncology.
VCYT Faces Reimbursement and Execution Risks
Prosigna has not yet secured Medicare reimbursement, and Veracyte excluded both Prosigna LDT and TrueMRD revenues from 2026 guidance because commercialization remains early. Decipher also faces softer demand in low-risk prostate cancer following guideline changes.
The Veracyte SAS exit adds another reset. Biopharmaceutical and other revenues fell to $0.8 million in the second quarter from $4.3 million a year earlier, increasing dependence on testing revenues. Higher investment adds execution pressure, with non-GAAP research and development expense rising to $26.3 million from $14.3 million.
Veracyte’s Valuation Leaves Less Room for Error
The recent decline has not made VCYT inexpensive relative to its group. The stock trades at 5.3X forward 12-month sales, above the Zacks sub-industry’s 4.2X multiple and slightly above its five-year median of 5.2X.
Image Source: Zacks Investment Research
That premium leaves less room for setbacks in reimbursement or launch execution. Still, the balance sheet provides flexibility. Veracyte ended the second quarter with $485.2 million in cash, cash equivalents and short-term investments and no current debt.
VCYT’s Signals Mix Strength With Caution
The sell-off has created a better price than a month ago, but the case is not purely valuation driven. Core test demand, raised 2026 revenue guidance and a debt-free balance sheet support the operating outlook, while reimbursement and commercialization risks argue for selectivity.
VCYT currently carries a Zacks Rank #1 (Strong Buy), reflecting favorable near-term earnings-estimate revisions. The Zacks Consensus Estimate for 2026 earnings has risen 3.9% in the past four weeks. Its Momentum Score of B is supportive, but the Growth Score of C, Value Score of D and VGM Score of D show that the stock does not score favorably across all investing styles. The combination points to stronger near-term estimate momentum, tempered by valuation and broader style considerations.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.